Procter & Gamble Health Ltd (BSE: 500126) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹9,638 Cr, it ranks #604 by market cap among the 6,197 Indian listed companies on FinBizNet, and #20 of 86 in Medicinal Chemicals and Botanical Products. At ₹5,870.00 (as of 16 Nov 2026), the share price is 15.8% below its 52-week high of ₹6,975.00 and 24.7% above its 52-week low of ₹4,707.00. The share price is down 3.1% over one year and down 1.9% over three months.
| Current Price | ₹5,870.00 |
|---|---|
| Market Cap | ₹9,638 Cr |
| BSE Code | 500126 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 29.3 |
| Return on Equity | 61.59% |
| Return on Assets | 33.24% |
| 52-Week Range | ₹4,707.00 – ₹6,975.00 |
| 1-Year Price Change | -3.1% |
| 3-Month Price Change | -1.9% |
| Beta (1Y) | 0.15 |
| Dividend Yield | 1.56% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.pghealthindia.com |
| Revenue | ₹382 Cr |
|---|---|
| Net Profit | ₹112 Cr |
| Net Margin | 29.2% |
| EPS (Basic) | ₹67.18 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Procter & Gamble Health Ltd reported revenue of ₹382 Cr in Q2 FY27, up 17.7% from ₹325 Cr in Q2 FY26 and up 5.2% from ₹364 Cr in Q1 FY27. It posted a net profit of ₹112 Cr for the quarter, against a net profit of ₹89 Cr in Q2 FY26 (up 25.9%). Across the 6 quarters from Q1 FY26 to Q2 FY27, quarterly revenue ranged from ₹325 Cr (Q2 FY26) to ₹382 Cr (Q2 FY27). The company was profitable in each of these 6 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹382 Cr | ₹112 Cr | 29.2% |
| Q1 FY27 | ₹364 Cr | ₹96 Cr | 26.4% |
| Q4 FY26 | ₹370 Cr | ₹95 Cr | 25.5% |
| Q3 FY26 | ₹374 Cr | ₹78 Cr | 20.8% |
| Q2 FY26 | ₹325 Cr | ₹89 Cr | 27.2% |
| Q1 FY26 | ₹339 Cr | ₹66 Cr | 19.5% |
Standalone figures (₹ crore, XBRL filings).
Promoters held 51.82% of Procter & Gamble Health Ltd's shares as of Sept 2026, unchanged from Sept 2025. Delivery averaged 52.0% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Procter & Gamble Health Limited manufactures and markets pharmaceuticals and chemical products in India and internationally. The company offers over-the-counter products, vitamins, minerals, and supplements. It offers its products under the Polybion, Cosome, Evion, Neurobion, Nasivion, Livogen, and Seven Seas brands. The company was formerly known as Merck Limited and changed its name to Procter & Gamble Health Limited in May 2019. Procter & Gamble Health Limited was incorporated in 1967 and is headquartered in Mumbai, India. Procter & Gamble Health Limited is a subsidiary of Procter & Gamble Overseas India B.V.
1. Segment Adjustment-This segment engages in the pharmaceuticals business. 2. Pharmaceuticals-0 3. Chemicals-This segment offers bulk drugs and pigments. 4. Corporate-0
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Procter & Gamble Health Ltd | ₹9,638 Cr | 29.3 | 61.59% | ₹382 Cr | -3.1% |
Listed by market capitalisation. Ratios are shown for context only.
Procter & Gamble Health Ltd is trading at ₹5,870.00, with a market capitalisation of ₹9,638 Cr.
Procter & Gamble Health Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Procter & Gamble Health Ltd has a P/E of 29.3 and a return on equity of 61.59%.
Procter & Gamble Health Ltd is listed on the BSE under the scrip code 500126.
Procter & Gamble Health Ltd's share price is down 3.1% over one year and down 1.9% over three months. Its 52-week range is ₹4,707.00 to ₹6,975.00.
In Q2 FY27, Procter & Gamble Health Ltd reported revenue of ₹382 Cr and net profit of ₹112 Cr, with basic EPS of ₹67.18 (standalone, parsed from the company's exchange filing).
Procter & Gamble Health Ltd reported revenue of ₹382 Cr in Q2 FY27, up 17.7% from ₹325 Cr in Q2 FY26 and up 5.2% from ₹364 Cr in Q1 FY27.
Promoters held 51.82% of Procter & Gamble Health Ltd's shares as of Sept 2026, unchanged from Sept 2025.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.